Dyslipidemia Study Investigating The Increase In "Good Cholesterol"
Public ClinicalTrials.gov record NCT00169559. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Three-staged, Randomized, Parallel Group, Sequential, Double-blind, fenofibrate-and Placebo-controlled Dose-response Evaluation of the Safety, Tolerability, and Effects on Plasma HDLc and TG of Eight Weeks Treatment With 1µg to 20µg Daily Doses of GW590735 in Otherwise Healthy Subjects With Low HDLc, Mildly to Moderately Elevated TG, and Normal LDLc
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
An eight week comparison of the investigational drug GW590735, placebo, and the marketed drug fenofibrate intended to increase the levels of "good cholesterol" and decrease levels of "bad cholesterol" in healthy patients with low levels of good cholesterol and high levels of bad cholesterol.
Study identification
- NCT ID
- NCT00169559
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 250 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2003 (Type not available)
- Primary completion
- Apr 2005 (Actual)
- Completion
- Apr 2005 (Actual)
- Last update posted
- Oct 22, 2012
2003 – 2005
United States locations
- U.S. sites
- 45
- U.S. states
- 20
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35243 | — |
| GSK Investigational Site | Phoenix | Arizona | 85014 | — |
| GSK Investigational Site | Phoenix | Arizona | 85050 | — |
| GSK Investigational Site | Scottsdale | Arizona | 85251 | — |
| GSK Investigational Site | Beverly Hills | California | 90210 | — |
| GSK Investigational Site | Healdsburg | California | 95448 | — |
| GSK Investigational Site | Orange | California | 92868 | — |
| GSK Investigational Site | Spring Valley | California | 91978 | — |
| GSK Investigational Site | Walnut Creek | California | 94598 | — |
| GSK Investigational Site | DeLand | Florida | 32720 | — |
| GSK Investigational Site | Fort Lauderale | Florida | 33308 | — |
| GSK Investigational Site | Fort Lauderdale | Florida | 33145 | — |
| GSK Investigational Site | Fort Lauderdale | Florida | 33308 | — |
| GSK Investigational Site | Hollywood | Florida | 33021 | — |
| GSK Investigational Site | Jacksonville | Florida | 32205 | — |
| GSK Investigational Site | Jacksonville | Florida | 32216 | — |
| GSK Investigational Site | Pembroke Pines | Florida | 33024 | — |
| GSK Investigational Site | Orland Park | Illinois | 60462 | — |
| GSK Investigational Site | Evansville | Indiana | 47714 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46260 | — |
| GSK Investigational Site | Iowa City | Iowa | 52242 | — |
| GSK Investigational Site | Louisville | Kentucky | 40213 | — |
| GSK Investigational Site | Auburn | Maine | 04210 | — |
| GSK Investigational Site | Brooklyn Center | Minnesota | 55430 | — |
| GSK Investigational Site | Omaha | Nebraska | 68131 | — |
| GSK Investigational Site | Endwell | New York | 13760 | — |
| GSK Investigational Site | New York | New York | 10021 | — |
| GSK Investigational Site | Rochester | New York | 14609 | — |
| GSK Investigational Site | Williamsville | New York | 14221 | — |
| GSK Investigational Site | Statesville | North Carolina | 28677 | — |
| GSK Investigational Site | Wilmington | North Carolina | 28412 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45219 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45246 | — |
| GSK Investigational Site | Medford | Oregon | 97504 | — |
| GSK Investigational Site | Allentown | Pennsylvania | 18102 | — |
| GSK Investigational Site | Erie | Pennsylvania | 16506 | — |
| GSK Investigational Site | Sioux Falls | South Dakota | 57105 | — |
| GSK Investigational Site | Bristol | Tennessee | 37620 | — |
| GSK Investigational Site | Kingsport | Tennessee | 37660 | — |
| GSK Investigational Site | Bryan | Texas | 77802 | — |
| GSK Investigational Site | Conroe | Texas | 77304 | — |
| GSK Investigational Site | Houston | Texas | 77030 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | Norfolk | Virginia | 23502 | — |
| GSK Investigational Site | Richmond | Virginia | 23294 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00169559, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 22, 2012 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00169559 live on ClinicalTrials.gov.